佐剂在钩端螺旋体疫苗中的应用与未来研发挑战
钩端螺旋体病是全球重要的被忽视传染病,疫苗是最可行的控制策略,但目前仅有灭活菌体疫苗获批,存在血清型依赖和免疫期短等缺点。本文综述了重组蛋白疫苗和DNA疫苗等新型疫苗中佐剂的应用,包括铝盐、油乳佐剂、细菌来源成分和脂质体,并强调佐剂对诱导保护性免疫应答的关键作用。
要点
- 灭活菌体疫苗是当前唯一可选疫苗,但存在血清型依赖和短期免疫的缺陷。
- 仅古巴、法国和中国批准灭活菌体疫苗用于高危人群。
- 佐剂对重组蛋白疫苗和DNA疫苗诱导保护性免疫应答至关重要。
核心结论
- 佐剂是新型钩端螺旋体疫苗诱导保护性免疫应答的关键组分,免疫应答数据有助于理解保护机制并推动有效疫苗研发。
研究设计与样本
- 本文为综述,聚焦钩端螺旋体疫苗中佐剂的应用及其重要免疫学方面,是首篇以佐剂为重点的钩端螺旋体疫苗综述。
主要发现
- 灭活菌体疫苗存在血清型依赖和短期免疫等缺点,未在人类中广泛使用。
- 重组蛋白疫苗或DNA疫苗是有吸引力的策略,但佐剂对实现保护性免疫应答至关重要。
- 已测试的佐剂包括铝盐、油基乳剂佐剂、细菌来源成分和脂质体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Leptospirosis is a neglected infectious disease of global importance. Vaccination is the most viable strategy for the control of leptospirosis, but in spite of efforts for the development of an effective vaccine against the disease, few advances have been made, and to date, bacterin is the only option for prevention of leptospirosis. Bacterins are formulations based on inactivated leptospires that present a series of drawbacks, such as serovar-dependence and short-term immunity. Therefore, bacterins are not widely used in humans, and only Cuba, France and China have these vaccines licensed for at-risk populations. The development of recombinant DNA technology emerges as an alternative to solve the problem. Recombinant protein-based vaccines or DNA vaccines seem to be an attractive strategy, but the use of adjuvants is critical for achievement of a protective immune response. Adjuvants are capable of enhancing and/or modulating immune responses by exposing antigens to antigen-presenting cells. In the last years, several components have been tested as adjuvants, such as aluminum salts, oil based-emulsion adjuvants, bacteria-derived components and liposomes. This review highlights the use of adjuvants in the multiple vaccine approaches that have been used for leptospirosis and their most important immunological aspects. Immune response data generated by these strategies can contribute to the understanding of the immune mechanisms involved in protection against leptospirosis, and consequently, the development of effective vaccines against this disease. This is the first review on leptospiral vaccines focusing on adjuvant aspects.
引用
- Teixeira AF, Fernandes LGV, Cavenague MF, et al. Adjuvanted leptospiral vaccines: Challenges and future development of new leptospirosis vaccines. Vaccine. 2019. PMID: 31186193. doi:10.1016/j.vaccine.2019.05.087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。